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Cancer of unknown primary site (CUP) represents up to 5% of all cancer diagnoses and is associated with poor survival. We have
performed a prospective multicentre phase 2 trial to evaluate efficacy and toxicity of the combination of gemcitabine (G) and
carboplatin (C) for patients with CUP. Patients with histologically confirmed metastatic carcinoma in which the primary site of cancer
was not evident after prospectively designated investigation and who had ECOG performance status 0–2 were treated with G
1000mgm
 2 intravenously (i.v.) days 1 and 8, and C AUC 5 i.v. on day 8 every 3 weeks to a maximum of nine cycles. The primary
end points were response rate, and toxicity, with secondary end points of progression-free survival and overall survival. Fifty-one (23
male, 27 female) patients were enrolled (one patient ineligible), with a median age of 69 years (range 41–83 years). Fifty patients
were evaluable for toxicity and 46 patients were evaluable for efficacy. The overall response rate to the GC regimen was 30.5%. With
a median follow-up of 24 months, the median progression-free survival was 18 weeks (4.2 months) and the median overall survival
was 34 weeks (7.8 months). The frequency of grade 3 or 4 toxicity was low. Nausea/vomiting was the most common side effect, but
was usually only mild in severity. Uncomplicated neutropenia (14%), thrombocytopenia (10%) and anaemia (8%) were the most
common causes of grade 3–4 toxicity. The regimen was very well tolerated, particularly in the elderly. The GC regimen is an active
regimen in CUP with excellent tolerability and should be considered particularly for elderly patients with CUP.
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Cancer of unknown primary site (CUP) represents up to 5% of all new
cancer diagnoses, of which 60% are adenocarcinomas. When CUP is
diagnosed in the absence of specific symptoms to suggest a primary
site of malignancy, there is a high chance that extensive evaluation
will not identify a primary site (Greco and Hainsworth, 2001).
There are several clinical circumstances when specific sub-
groups of patients presenting with CUP may be treated with
tumour-specific chemotherapy, with an expectation of significant
efficacy. These include: (i) peritoneal carcinomatosis or malignant
ascites in women, particularly with serous cancers where ovarian
cancer protocols are often effective, (ii) women with axillary lymph
node metastases where treatment for occult breast carcinoma has
been shown to be effective, (iii) male patients with osteoblastic
bone metastases where empiric hormonal manipulation for
metastatic prostate cancer would seem worthwhile, (iv) young
males with undifferentiated carcinomas, involving retroperitoneal
mediastinal lymph nodes where empirical treatment for germ cell
tumour may be appropriate, (v) patients who present with
metastatic squamous cell carcinoma in high cervical nodes where
radical treatment for head and neck cancer is usually undertaken
(Lenzi et al, 1997).
However, about 90% of patients with CUP are not in the clinical
subgroups previously outlined. Various combinations of chemo-
therapy have been shown to have some effect in these circum-
stances. Response rates range from 0 to 50% with an average
response rate of about 20–30%. Some of the most active older
combinations have contained doxorubicin or cisplatin (Sporn and
Greenberg, 1993; Parnis et al, 2000). More recently, newer
cytotoxics, such as taxanes, irinotecan and gemcitabine (G), have
been used in combination chemotherapy with more consistent
response rates in the order of 25–40%, although some of these
combinations have been associated with significant toxicity (Greco
et al, 2002; Culine et al, 2003; Park et al, 2004).
In most series, the median survival rate for patients treated for
CUP is 6–8 months. As such, all treatment in this clinical setting
should be considered palliative. A concern with many combina-
tions, including those containing agents such as doxorubicin,
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scisplatin, etoposide, taxanes and irinotecan, is that they are likely
to produce significant toxicity, such as nausea/vomiting, myelo-
suppression and alopecia. Despite the significant improvement in
general community education about cancer and cytotoxic chemo-
therapy, the side effects of nausea/vomiting and alopecia remain
high on the list of patient concerns when confronting chemother-
apy treatment. Clearly, combinations with good efficacy but
with better side-effect profile are warranted in the palliative
setting of CUP.
Platinum-based doublets or triplets remain the most commonly
reported protocols for CUP. Carboplatin (C) is often now used in
numerous clinical situations where cisplatin was traditionally
considered standard. Carboplatin produces more myelosuppres-
sion than cisplatin, but has the advantage of inducing less nausea,
vomiting and neurotoxicity.
Gemcitabine as a single agent has been shown to have significant
activity in small-cell and nonsmall-cell lung cancer, breast
cancer, ovarian cancer, hormone refractory prostate cancer,
pancreatic cancer, bladder cancer, lymphoma and head and
neck cancer. Its major toxicity is myelosuppression, which
tends to be dose dependant. Although gemcitabine is now
approved and licensed in Australia for numerous malignancies,
at the time this trial was commenced in 2001, it was only routinely
available in Australia in the settings of lung cancer and pancreatic
cancer.
The combination of GC has the advantage of being able to be
administered rapidly in an outpatient setting with myelosuppres-
sion (usually dose dependent) being the only frequent major
toxicity. Significant nausea, vomiting and alopecia are rare. The
GC combination has now been reported in numerous clinical
situations, including nonsmall-cell lung cancer, bladder cancer and
ovarian cancer with good tolerance and significant activity (Langer
et al, 1998; Linardou et al, 2004; Pfisterer et al, 2005; Sedeholm
et al, 2005). The spectrum of activity of the GC combination is
such that it would appear to be an ideal combination to use in the
management of CUP, provided that colorectal cancer can be
reasonably excluded.
We instigated a prospective open-label phase 2 trial to
determine the efficacy and tolerability of the GC combination as
first-line therapy in CUP patients presenting to cancer centres
across metropolitan Adelaide in South Australia, Australia.
PATIENTS AND METHODS
Patients who presented to cancer centres in Adelaide,
South Australia with histologically confirmed metastatic carcino-
ma (proven by immunohistochemistry) for which no primary
site of disease was found after standard evaluation were eligible for
study. Only cases of adenocarcinoma, large-cell carcinoma,
undifferentiated carcinoma and carcinoma ‘not otherwise
specified’ were included. Squamous cell carcinoma, small-cell
carcinoma/neuroendocrine carcinoma and serous/papillary carci-
noma were not included. Prior chemotherapy for CUP was not
permitted.
Routine evaluation included CT scan of chest, abdomen and
pelvis, mammography in the female patient, CA125 in the female
patient, and PSA, alpha feto-protein and betaHCG in the male
patient. Additionally, designated investigation of the following
scenarios was mandatory: upper GI endoscopy for a history of
significant dysphagia or marked dyspepsia or intermittent
epigastric pain; colonoscopy for a history of recent change in
bowel symptoms, rectal bleeding or iron deficiency anaemia, or
significantly elevated CEA level; bronchoscopy for a history of
recent change in cough or wheeze or history of haemoptysis; and
cystoscopy for a history of recent haematuria.
Patients had to be 18 years of age or over and had to have ECOG
performance status of 0–2. Adequate haematological, hepatic and
renal function as directed by protocol was mandatory. Patients had
to have a life expectancy of greater than 3 months in the opinion of
the treating clinician. Patients were required to give written
informed consent before commencement of any specific studies
and specific investigations and had to be willing and able to
comply with the protocol for the duration of the study. Patients
with either measurable or evaluable disease were eligible. The
study was approved by the ethics committees of each of the
treating institutions.
Patients who entered the trial underwent treatment with G
1000mgm
 2 as a 30min infusion on days 1 and 8, with C
administered in an AUC5 (calculated using the Calvert formula
(Calvert et al, 1989)) over 1h on day 8, with treatment repeated on
a 3 weekly basis. The antiemetic regimen was left to the discretion
of investigator/clinician.
During treatment, patients were reviewed on days 1 and 8 of
each treatment cycle and underwent general physical examination,
toxicity assessment and assessment of ECOG performance status.
Haematological and biochemical indices were checked on days 1
and 8.
Formal tumour evaluation was performed after every third cycle
of chemotherapy. Response evaluation was determined according
to WHO criteria (Miller et al, 1981). Quality of life evaluation was
performed at baseline and after every third cycle of chemotherapy.
Dose reductions were determined by protocol-defined observed
toxicities and were based upon the starting dose. Dose escalations
were not allowed and colony-stimulating factors (CSFs) were not
permitted in this study. Patients with objectively defined tumour
progression were withdrawn from the study. Patients could be
withdrawn from study at discretion of investigator/clinician or at
the request of the patient. Patients could continue with treatment
regimen to a maximum of nine cycles if there was no evidence of
tumour progression and good tolerability.
The total sample size required to demonstrate a response rate of
40%, assuming a historical response rate of 20%; was 50 patients,
with 90% power, a significance level of 0.05, and two-sided
significance testing (Fleming, 1982).
RESULTS
Between June 2001 and January 2004, 51 patients were entered into
the trial. One patient was excluded as the primary site of cancer
(colon) was discovered during the first cycle of treatment. Fifty
patients were therefore available for toxicity analysis. Forty-six
patients were eligible for response analysis. Four patients could not
be fully evaluated for response owing to early withdrawal or death
within the first 3 weeks of therapy. Response was analysed
according to both evaluable and ‘intention-to-treat’ (ITT) criteria.
All patients were included in progression-free survival and overall
survival analysis. Patient characteristics and treatment parameters
are detailed in Table 1.
The mean relative dose intensity (RDI) achieved was 0.80 of the
planned dose. The median RDI for patients receiving four cycles or
more was 0.86 of the planned dose.
Toxicity
Median number of cycles of chemotherapy was four (range 1–9).
The side effects of the chemotherapy protocol were as described in
Table 2.
Forty-eight per cent of patients experienced a grade 3 or greater
toxicity. The majority of this was haematological toxicity: 14%
neutropenia, 10% anaemia, and 8% thrombocytopenia. The febrile
neutropenia rate was 6%. There was no alopecia and only one
episode of grade 3 nausea. There was one death that may be partly
attributed to neutropenic sepsis. This patient had significant
pulmonary metastases and malignant pleural effusion and
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spresented with respiratory failure, renal failure and febrile
neutropenia. He died shortly after admission to hospital.
Efficacy
The response rate for evaluable patients was 30.5% (95% CI 19–
44%). By ITT analysis the response rate was 28% (95% CI 15–
40%). The median duration of response among the responders was
39 weeks (9 months). The ‘best outcome’ achieved in the
nonresponders was 39% stable disease and 30% disease progres-
sion. Median progression-free survival for all patients (ITT) was 18
weeks (4.2 months) range 2–102þ weeks (95% CI 10–26 weeks)
(see Figure 1). The median overall survival was 34 weeks (7.8
months) range 2–141 weeks (95% CI 19–44 weeks) (see Figure 2).
The 12-month survival rate was 26% and the 24-month survival
rate was 12%.
Subgroup analysis is depicted in Table 3. Whereas women had
an overall better response rate than men, there was no difference in
survival between the sexes. No significant median survival
differences were observed with respect to sites of metastatic
disease. There was an apparent trend towards greater response rate
and survival with better performance status.
There was a trend towards greater response rates with increasing
age. Patients aged less than 65 years had a response rate of 15%
compared with 40% for patients aged 65 years or older. There was,
however, similar overall survival for most patient age subgroup-
ings, except for a small subgroup of patients aged less than 50
years with a median survival of 22 weeks.
DISCUSSION
Fifteen years ago, the incidence of CUP was reported to be 5–10%.
With improvements in diagnostic procedures, both in terms of
accuracy and comfort, the current incidence of CUP is now
reported as 2–5%. However, despite these substantial improve-
ments in diagnostic procedures, a significant number of cancer
patients will not have the primary site of their cancer discovered.
Therefore, palliative chemotherapy protocols with a broad range of
Table 1 Patient characteristics (N¼50)
Characteristic No. of patients %
Age (years)
Median 69
Range 41–83
Sex
Male 23 46
Female 27 54
ECOG status
01 0 2 0
12 8 5 6
21 2 2 4
Sites of disease
Liver 38 76
Lung 16 32
Retroperitoneal adenopathy 10 20
Peritoneum/mesenteric nodes 6 12
Bone 6 12
Pleura 5 10
No. of cycles of chemotherapy
Median 4
Range 1–9
ECOG¼Eastern Cooperative Oncology Group.
Table 2 Incidence of grade 3–4 toxicity
Grade 3/4 toxicity Incidence (%)
Neutropenia 14 (including one death)
Anaemia 10
Thrombocytopenia 8
Thromboembolism 6
Progression-free survival
Median PFS 18 weeks 
(95% CI 10–26 weeks) 
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Figure 1 Kaplan–Meier plot of progression-free survival – all patients
(ITT).
Overall survival
Median OS 34 weeks 
(95% CI 19–44 weeks) 
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Figure 2 Kaplan–Meier plot of overall survival – all patients (ITT).
Table 3 Response and survival by sex, performance status and age
criteria
Characteristic % Response Median survival (weeks)
Male 19 33
Female 40 36
PS 0 40 58
PS 1 28 33
PS 2 16 18
Age o65 years 15 30
Age X65 years 40 38
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sactivity are still required for this clinical scenario. The challenge is
to develop cytotoxic chemotherapy regimens that have a broad
level of activity with minimal toxicity.
Historically, CUP regimens have often included fluoropyrimi-
dines because of the predominance of occult GI primaries in this
scenario. Because of the improvements in outcomes with
chemotherapy for metastatic colorectal cancer and the relative
ease of colonoscopy, colorectal cancer is nowadays specifically
screened for in the setting of newly diagnosed CUP. With
colorectal cancers being more routinely excluded in the diagnostic
work-up, fluorouracil has become a less important agent in
combination chemotherapy for CUP.
More recently, agents including taxanes, etoposide, gemcitabine
and irinotecan have been used in combination with platinum
compounds with apparent improved response rates and survival
times. A 39% response rate with a 13-month median survival was
achieved in a group of 77 CUP patients with a median age of 60
years who were treated with the carboplatin/paclitaxel combina-
tion (Briasoulis et al, 2000). The triplet of carboplatin/gemcitabine/
paclitaxel followed by weekly paclitaxel for responders was used in
120 CUP patients with a median age of 59 years, and for these
patients, a 25% overall response rate was achieved with a median
survival of 9 months (Greco et al, 2002). In both of these studies,
alopecia was almost universal and grade 3/4 myelosuppression was
common, although CSFs were frequently used. Significant neuro-
pathy was also common.
The GC combination used in our study could be reasonably used
as first-line therapy in the setting of nonsmall-cell lung cancer,
pancreatic/biliary cancer, bladder cancer, ovarian cancer and
could be a valid second line combination for breast cancer. It has
some activity in gastric cancer, but would certainly be considered
an inferior treatment for colorectal cancer. The slightly lower dose
of gemcitabine used in this study and the absence of taxane from
the regimen has meant that toxicity was substantially reduced. In
particular, there was almost no alopecia or neuropathy. Although
CSFs were not used, the rate of significant myelosuppression was
low.
The median age of the patients in this study was 69 years, about
a decade older than the two previously described studies
(Briasoulis et al, 2000, Greco et al, 2002). The response rate and
overall survival achieved in our study is less than that demon-
strated by Briasoulis et al (2000). It should be noted, however, that
21% of the patients entered in the Briasoulis study were women
with peritoneal carcinomatosis who achieved a response rate of
81% (to paclitaxel/carboplatin) and it is possible that the inclusion
of these patients may have substantially increased the overall
response rate for the whole group. The response rate and overall
survival in our study is more consistent with that of the study of
Greco et al (2002), where there appears to have been tighter
inclusion criteria.
Several studies have evaluated prognostic factors in CUP
patients including sex, sites of disease, performance status and
certain blood parameter variables. Some have suggested that male
patients and presence of liver metastases were independent poor
prognostic variables (Culine et al, 2002). However, in our study,
while some of these parameters appeared to be associated with
lower response rates, they did not appear to influence overall
survival. The only variables that appeared to be associated with
both lower response rate and lower overall survival were PS 2 and
patients aged less than 50 years, although these subgroups
constituted a small number of patients only.
Older patients in particular appeared to have a higher response
rate with this regimen and median overall survival of this group
was at least as good as the median survival for the whole group.
Elderly women seemed to fare particularly well. Mammography
was routine for all women entering the study and reasonable
means to exclude likely ovarian or primary peritoneal carcinoma
was routinely undertaken. For the four women in the trial who had
peritoneal or mesenteric adenopathy as part of their disease, all
had other sites of disease, including liver, lung or retroperitoneal
adenopathy and all had tumour immunohistochemistry evaluation,
which was more consistent with gastrointestinal cancer than
gynaecological cancer. Two of these patients achieved a response.
If occult breast cancer or ovarian cancer with variant histology was
over-represented in this subgroup, then this may partly explain the
better responses and outcomes. However, the results suggest that a
pragmatic treatment approach of GC in such cases can be applied
with reasonable efficacy. Additionally, the dosing and scheduling
of this GC combination chosen was very tolerable in the elderly so
that advanced age alone should not be a contraindication to
treatment.
It is likely that genetic profiling of CUP in the future may not
only vastly improve the likelihood of a primary site being
eventually discovered, but may also dictate the appropriate
treatment strategies regardless of possible primary sites. However,
until such approaches are fully validated, regimens with a broad
range of activity with good tolerability will be required to manage
this common clinical entity. From a pragmatic viewpoint, when
CUP is diagnosed in the absence of specific clinical situations that
require tumour-specific treatment approaches, and if a colorectal
primary can be reasonably excluded, the GC combination provides
an active and very well-tolerated treatment regimen that is
particularly applicable to the elderly population.
ACKNOWLEDGEMENTS
This study was supported by a grant from Eli Lilly Australia.
ACTEC is grateful for the support of the Cancer Council of South
Australia. We would like to thank all of the medical staff, nursing
staff and data managers at The Queen Elizabeth Hospital, Royal
Adelaide Hospital, Flinders Medical Centre and Ashford Hospital
who collaborated on this trial.
REFERENCES
Briasoulis E, Kalofonos H, Bafaloukas D, Samantas E, Fountzilas G, Xiros N,
Christodoulou C, Kosmidis P (2000) Carboplatin plus paclitaxel in
unknown primary cancer: a phase 2 Hellenic co-operative oncology
group study. J Clin Oncol 18: 3101–3107
Calvert H, Newell D, Gumbrell L (1989) Carboplatin dosage: a prospective
evaluation of a simple formula based upon renal function. J Clin Oncol 7:
1748–1756
Culine S, Kramar A, Saghatchian M, Bugat R, Lesimple T, Lortholary A,
Merrouche Y, Laplanche A, Fizari K (2002) Development and validation
of a prognostic model to predict the length of survival in patients with
carcinomas of unknown primary site. J Clin Oncol 20: 4679–4683
Culine S, Loertholary A, Voigt J, Bugat R, Theodore C, Priou F, Kaminsky
M, Lesimple T, Pivot X, Coudert B, Douillard J, Merrouche Y, Allouache
A, Goupil A, Negrier S, Viala J, Petrow P, Bouzy J, Laplanche A, Fizazi K
(2003) Cisplatin in combination with either gemcitabine or irinotecan in
carcinomas of unknown primary site: results of a randomised phase II
study – Trial of the French Study Group on carcinomas of unknown
primary (GEFCAPI). J Clin Oncol 21: 3479–3482
Fleming TR (1982) One-sample multiple testing procedure for phase II
clinical trials. Biometrics 38: 143–151
Greco F, Burris H, Litchy S, Barton J, Bradof J, Richards P, Scullin D, Erland
J, Morrissey L, Hainsworth J (2002) Gemcitabine, carboplatin and
Gemcitabine and carboplatin in carcinoma of unknown primary
KB Pittman et al
1312
British Journal of Cancer (2006) 95(10), 1309–1313 & 2006 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
spaclitaxel for patients with carcinoma of unknown primary site: a Minnie
Pearl Cancer Research Network Study. J Clin Oncol 20: 1651–1656
Greco F, Hainsworth J (2001) Cancer of unknown primary site. In: Cancer;
Principles and Practice of Oncology De Vita V, Hellman S, Rosenberg S
(eds), 6th edn, pp 2537–2560. Philadelphia: Lippincott
Langer C, Calvert P, Ozols R (1998) Gemcitabine and carboplatin in
combination: phase 1 and 2 studies. Semin Oncol 25(4, Suppl 9): 51–54
Lenzi R, Hess K, Abbruzzese M, Raber M, Ordonez N, Abbruzzese J (1997)
Poorly differentiated carcinoma and poorly differentiated carcinoma of
unknown origin: favourable subsets of patients with unknown primary
carcinoma? J Clin Oncol 15: 2056–2066
Linardou H, Aravantinos G, Efstathious E, Kalafonos C, Anagnostopoulos
A, Delveliotis C, Bafaloukos D, Athanasios Dimoloulos M, Bamias A
(2004) Gemcitabine and carboplatin as first line treatment in elderly
patients and those unfit for cisplatin based chemotherapy with advanced
bladder carcinoma: a phase 2 study of the Hellenic co-operative oncology
group. Urology 64: 479–484
Miller A, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of
cancer treatment. Cancer 47: 207–214
Park Y, Ryoo B, Choi S, Yang S, Kim H (2004) A phase 2 study of
paclitaxel plus cisplatin chemotherapy in an unfavourable group
of patients with cancer of unknown primary site. Jpn J Clin Oncol 34:
681–685
Parnis F, Olver I, Kotasek D, Norman J, Taylor A, Russell J, Patterson K,
Keefe D, Marafioti T (2000) Phase 2 study of epirubicin, cisplatin and
continuous infusion 5-fluorouracil (ECF) for carcinoma of unknown
primary site. Ann Oncol 11: 883–884
Pfisterer J, Vergote I, Du Bois A, Eisenhuer E (2005) Combination
chemotherapy with gemcitabine and carboplatin in recurrent ovarian
cancer. Int J Gynaecol Cancer 15(Suppl 1): 36–41
Sedeholm C, Hillerdal G, Lamberg K, Kolbeck K, Dufmats M,
Westberg R, Gawande S (2005) Phase 3 trial of gemcitabine
plus carboplatin versus single agent gemcitabine in the treatment
of locally advanced or metastatic non-small cell lung cancer:
The Swedish Lung Cancer Study Group. J Clin Oncol 23: 8380–
8388
Sporn J, Greenberg B (1993) Empirical therapy for adenocarcinoma of
unknown primary tumor site. Semin Oncol 20: 261–270
Gemcitabine and carboplatin in carcinoma of unknown primary
KB Pittman et al
1313
British Journal of Cancer (2006) 95(10), 1309–1313 & 2006 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s